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34 The Journal of Thoracic and CardiovObjective: We sought to assess the role of glucose-insulin-potassium in providing
myocardial protection in nondiabetic patients undergoing coronary artery surgery
with cardiopulmonary bypass.
Methods: A prospective, randomized, double-blind, placebo-controlled trial was
conducted at a single-center university hospital performing adult cardiac surgery.
Two hundred eighty nondiabetic adult patients undergoing first-time elective or
urgent isolated multivessel coronary artery bypass grafting were prospectively
randomized to receive glucose-insulin-potassium infusion or placebo (dextrose 5%)
before, during, and for 6 hours after surgical intervention. Anesthetic, cardiopul-
monary bypass, myocardial protection, and surgical techniques were standardized.
The primary end point was postreperfusion cardiac index. Secondary end points
were systemic vascular resistance index, the incidence of low cardiac output
episodes, inotrope and vasoconstrictor use, and biochemical-electrocardiographic
evidence of myocardial injury. The incidence of dysrhythmias and infections
requiring treatment was recorded prospectively.
Results: The glucose-insulin-potassium group experienced higher cardiac indices (P
.001) throughout infusion and reduced vascular resistance (P  .001). The incidence
of low cardiac output episodes was 15.9% (22/138) in the glucose-insulin-potassium
group and 27.5% (39/142) in the placebo group (P .021). Inotropes were required
in 18.8% (26/138) of the glucose-insulin-potassium group and 40.8% (58/142) of
the placebo group (P  .001). Fewer patients in the glucose-insulin-potassium
group (12.3% [16/133]) versus those in the placebo group (23.4% [32/137]) had
significant myocardial injury (P  .017). Noncardiac morbidity was not different.
Conclusion: Glucose-insulin-potassium therapy improves early postoperative car-
diovascular performance, reduces inotrope requirement, and might reduce myocar-
dial injury. These potential benefits are not at the expense of increased noncardiac
morbidity.
During coronary artery bypass grafting grafting (CABG), the myocardiumendures periods of ischemia and reperfusion. For on-pump CABG, isch-emic protection is usually afforded by cardioplegia, which establishes
electromechanical arrest and reduces myocardial oxygen consumption. Despite this,
CABG might be followed by myocardial contractile dysfunction, which is associ-
ated with increased early and late morbidity and mortality and necessitates inotropic
and mechanical circulatory support.1,2 Metabolic modulation with glucose-insulin-
potassium (GIK) might improve myocardial protection, particularly in diabetic
patients.3 A survival benefit has been noted when early high-dose GIK has been
used after acute myocardial infarction,4-6 and GIK might reduce the requirement for
ascular Surgery ● January 2006
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Ppostsurgical circulatory support.7 Additionally, insulin ther-
apy in intensive care patients has been associated with
reduced mortality.8 A recent meta-analysis of 11 trials (n 
468) of GIK in cardiac surgery suggested that GIK im-
proved cardiac index (CI) and reduced inotrope requirement
and the incidence of atrial fibrillation (AF)9 and called for a
multicenter randomized controlled trial of GIK in cardiac
surgery. The aim of this study was to examine the effects of
GIK on cardiovascular performance and myocardial injury
in nondiabetic patients undergoing CABG.
Materials and Methods
A double-blind, prospective, randomized, placebo-controlled trial
was conducted in 280 patients undergoing isolated CABG between
January 2000 and August 2002. The study was approved by the
local research ethics committee, and all patients provided written
informed consent. Inclusion criteria were age of 18 years or older
and an intention to perform first-time multivessel CABG. Exclu-
sion criteria included diabetes mellitus, serum creatinine level of
200 mol/L or greater, recent (6 weeks) cerebrovascular event,
and emergency status. Before the trial, computer-generated ran-
domization schedules were generated in advance, stratified by
surgeon and left ventricular function, and placed in sequentially
numbered sealed envelopes. Trial investigators and medical and
nursing staff were blinded to allocation.
Trial Intervention
GIK and placebo (5% dextrose) solutions were independently
prepared immediately preoperatively in identical containers and
administered from sternotomy to 6 hours after release of the
aortic crossclamp as a continuous central intravenous infusion
at 0.75 mL · kg1 · h1. The GIK solution comprised 40%
dextrose containing 70 IU/L human Actrapid insulin (Novo
Nordisk A/S, Bagsvaerd, Denmark) and 80 mmol/L potassium
Abbreviations and acronyms
AF  atrial fibrillation
ANOVA analysis of variance
CABG  coronary artery bypass grafting
CI  cardiac index
CPB  cardiopulmonary bypass
cTnI  cardiac troponin I
ECG  electrocardiogram
GIK  glucose-insulin-potassium
IQR  interquartile range
ITU  intensive therapy unit
LCOE  episodes of low cardiac output
NYHA  New York Heart Association
PMI  perioperative myocardial infarction
SD  standard deviation
SVR  systemic vascular resistance
SVRI  systemic vascular resistance index
WBG  whole blood glucosechloride.
The Journal of ThoracAnesthetic, Operative, and Postoperative Protocols
Anesthesia, cardiopulmonary bypass (CPB), myocardial protec-
tion, and surgical techniques were standardized. Anesthesia was
induced with intravenous etomidate, fentanyl, and pancuronium
and maintained with enflurane, propofol, and alfentanil. CPB
(28°C) was instituted with a roller pump and membrane oxygen-
ator with an asanguineous prime. Intermittent antegrade cold blood
St Thomas’ No. 2 cardioplegia (Martindale Pharmaceuticals, Es-
sex, United Kingdom) containing no glucose was used for myo-
cardial protection (12 mL/kg for induction and 6 mL/kg at 20-
minute intervals). Distal anastomoses were constructed during a
single crossclamp period, and proximal anastomoses were con-
structed during partial aortic occlusion. After rewarming with a
37°C maximal heat-exchanger temperature, CPB was discontinued
at 36°C-37°C nasopharyngeal temperature. Intraoperative ventric-
ular tachydysrhythmias were treated with internal cardioversion or
lidocaine. Intravenous glycopyrollate, atropine, and atrial or dual-
chamber epicardial pacing were used to achieve a target heart rate
of 70 to 110 beats/min. Arterial whole blood glucose (WBG)
samples were drawn at baseline, every half hour before CPB, every
20 minutes during CPB, every hour for the initial 6 hours of
reperfusion, and every 2 hours for the subsequent 6 hours. Sup-
plemental insulin (human Actrapid, Novo Nordisk) was adminis-
tered according to a simple standardized sliding scale with a target
WBG value of 180 to 270 mg/dL. Patients with a WBG value of
180 to 270 mg/dL received a 4-IU intravenous bolus of insulin and
5 IU/h continuous intravenous infusion until the next test schedule,
and patients with a WBG value of 271 to 360 mg/dL received an
8-IU intravenous bolus and 10 IU/h continuous intravenous infu-
sion. Supplemental infused insulin was stopped 1 hour before trial
solution cessation in both groups and restarted 1 hour later accord-
ing to protocol. Inotropic support, initially with dopamine (3-10
g · kg1 · min1) and secondly with epinephrine, was com-
menced if the mean arterial pressure was less than 65 mm Hg with
a CI of 2.2 L · min1 · m2 or less in the presence of a central
venous pressure of 12 mm Hg, a pulmonary capillary wedge
pressure of 14 mm Hg, and a heart rate of 70 to 110 beats/min.
Support was also permitted if the operating surgeon identified poor
contractility at separation of CPB or if marginal hemodynamics
were noted by attending physicians. Intravenous vasoconstrictors
were used for a mean arterial pressure of less than 65 mm Hg, a
systemic vascular resistance (SVR) of less than 800 dynes · s1 ·
cm5, and a CI of greater than 3 L · min1 · m2. Bolus phenyleph-
rine was used until the administration of protamine, after which
norepinephrine infusion was used as a vasoconstrictor. Extubation,
intensive therapy unit (ITU), and hospital discharge criteria and AF
management were standardized.
Trial Investigations
Before surgical intervention, baseline demographic and clinical
data were recorded. Hemodynamic studies were performed before
infusion, before and 15 minutes after protamine administration,
and 2, 4, 6, 9, and 12 hours after reperfusion. Cardiac troponin I
(cTnI) samples were drawn at baseline and 6, 12, 24, 48, and 72
hours after reperfusion and analyzed in batches with a commercial
assay (Bayer Corp, Tarrytown, NY). Preoperative, postoperative
day 1, and postoperative 4 electrocardiograms (ECGs) were
obtained.
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The primary outcome measure was comparison of CI. Secondary
outcomes included systemic vascular resistance index (SVRI),
incidence of myocardial injury on ECG and enzymatic criteria,
episodes of low cardiac output (LCOE), and inotrope and vasocon-
strictor requirement. Perioperative myocardial infarction (PMI), as-
sessed by an independent cardiologist, was defined by the presence
of new left bundle branch block or new Q waves of 2 mm in depth
in 2 contiguous leads by postoperative day 4. Myocardial injury
was predefined as PMI, a cTnI value of 13.1 ng/mL, or both 6
hours after reperfusion.10 An LCOE, as assessed by a blinded
committee, was defined as a CI of 2.1 L · min1 · m2 or less with
a central venous pressure of 12 mm Hg and a pulmonary capillary
Figure 1. Cardiac index (CI), systemic vascular resista
(PCWP) in placebo (open diamonds) and glucose-insu
time points (mean  95% confidence intervals). Data a
variance (ANOVA; P < .001 for CI and SVRI). For indiv
.05. PCWP was not statistically different at any time point.
36 The Journal of Thoracic and Cardiovascular Surgery ● Januawedge pressure of 14 mm Hg in the presence of a native or paced
synchronized heart rate of greater than 70 beats/min. The individ-
ual total weight-indexed dose of dopamine was calculated. Serial
WBG concentrations and supplemental insulin requirements were
recorded. Reperfusion ventricular fibrillation was noted. Postoper-
ative atrial dysrhythmias were defined as those requiring pharma-
cologic or electrical cardioversion. Type I and II neurologic defi-
cits were diagnosed according to published criteria by attending
ITU physicians.11
Statistical Analysis
For 280 patients, the study had a 95% power to detect a change in
CI of 0.3 L · min1 · m2 at a significance level of 1% (assumed
ndex (SVRI), and pulmonary capillary wedge pressure
otassium (GIK; solid circles) groups at predetermined
is was performed with repeated-measures analysis of
time points, asterisks indicate a P value of less thannce i
lin-p
nalys
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Pstandard deviation [SD] of 0.6). Data were analyzed with SPSS
software. Categoric or ordinal data were compared by using 2
tests or Kendall tau b, respectively. Continuous data are presented
as means (95% confidence limits) unless stated otherwise. Nor-
mally distributed data were compared by means of independent t
test. Repeated-measures analysis of variance (ANOVA) was used
for serial measurements. Skewed data were either logarithmically
transformed or analyzed nonparametrically (Mann-Whitney U
test). The denominator for percentages accounts for missing data
(1.5% for any specific end point). We performed multivariable
binary logistic and linear regression analyses to identify predictors
of myocardial injury, LCOE, inotrope use, time to extubation, and
ITU and hospital length of stay.
Results
From 284 patients initially enrolled, 4 were excluded (post-
ponement of operation [n  2], new diabetes [n  1], and
a requirement for aortic valve replacement [n  1]). Of 280
patients studied, 138 were assigned to the GIK group, and
142 were assigned to the placebo group. There were no
differences between groups for demographic or intraopera-
tive variables, including angina status, priority, left ventric-
ular function, and medications (Table E1). Specifically,
there was no difference in the preischemic trial infusion
time (GIK mean, 82 minutes [SD, 23.8 minutes]; placebo
mean, 84 minutes [SD, 24.2 minutes]; P  .527), CPB time
(GIK mean, 88.3 minutes [SD, 25.2 minutes]; placebo mean,
88.8 minutes [SD, 28.4 minutes]; P  .858), and aortic cross-
clamp time (GIK mean, 48.9 minutes [SD, 15.6 minutes];
placebo, 47.5 minutes [SD, 18.5 minutes]; P  .508). There
Figure 2. Incidence (%) of low cardiac output episodes
myocardial injury in all patients, patients with New Yo
with a left ventricular ejection fraction (LVEF) of less than
The Journal of Thoracwere 5 (1.8%) deaths (GIK group, n  3; P  .68), and 8
patients (GIK group, n 4) required postoperative intra-aortic
balloon pump support. Patients in both groups received a
median of 3 grafts (interquartile range [IQR], 2-3).
Hemodynamic Effects
Baseline CI was not different (GIK group, 2.24 L · min1 ·
m2 [95% confidence limits, 2.14-2.74 L · min1 · m2];
placebo group, 2.16 L · min1 · m2, [95% confidence limits,
2.07-2.26 L · min1 · m2]; P .145), but patients in the GIK
group had a higher CI during infusion (P  .001). Baseline
SVRI was similar (GIK group, 2607 dynes · s1 · cm5 · m2
[95% confidence limits, 2459-2755 dynes · s1 · cm5 · m2];
placebo group, 2543 dynes · s1 · cm5 · m2 [95% confi-
dence limits, 2409-2677 dynes · s1 · cm5 · m2]; P  .72)
but was significantly lower in the GIK group during the infu-
sion (P  .001), increasing after infusion cessation (P  .41;
time points 0, 9, and 12 hours after aortic crossclamp removal;
Figure 1). Pulmonary capillary wedge pressure, central venous
pressure, and heart rate were not different between groups at
any time point.
Low Cardiac Output and Inotrope and
Vasoconstrictor Requirements
During the first 6 hours of reperfusion, the incidence of
LCOE was lower in the GIK group (GIK group, 22/138
[15.9%]; placebo group, 39/142 [27.5%]; P  .021; Figure
2). During this period, GIK particularly reduced the inci-
dence of LCOE in patients in New York Heart Association
E) and inotrope use 0 to 6 hours after reperfusion and
eart Association (NYHA) classes III or IV, and patients(LCO
rk H50%. GIK, Glucose-insulin-potassium.
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fraction of less than 50%.
Fewer patients in the GIK group received inotropic sup-
port in the first and subsequent 6 hours after reperfusion
(Figures 2 and 3), including patients in NYHA class III or
IV and with an ejection fraction of less than 50%, but more
patients required norepinephrine (0-6 hours after removal of
aortic crossclamp: GIK group, 96/138 [69.6%]; placebo
group, 65/142 [45.8%]; P  .001; 6-12 hours after removal
of aortic cross clamp: GIK group, 85/138 [61.6%]; placebo
group, 55/142 [38.7%]; P  .001). However, CI was sig-
nificantly higher in the GIK group before norepinephrine use
(P  .001), and data were concordant, regardless of need
for norepinephrine. If individual patients required ino-
tropes, the cumulative dose received was not different
between groups. Similarly, if norepinephrine was re-
quired, the dosage received was similar (GIK group, 20.9
mg/kg [95% confidence limits, 18.1-23 mg/kg]; placebo
group 20.6 mg/kg [95% confidence limits, 15.6-25.6 mg/
kg]; P  .99).
Myocardial Injury
The incidence of myocardial injury was lower in the GIK
group (GIK group, 16/133 [12.3%]; placebo group, 32/137
[23.4%]; P  .017; Figure 2). Electrocardiographic PMI did
not differ between groups (GIK group, 6/135 [4.4%]; pla-
cebo group, 10/140 [7.1%]; P  .442), but fewer patients in
Figure 3. Incidence of dopamine and epinephrine use
dosage of dopamine (mg/kg 102) or epinephrine (g
as an inotrope. Error bars represent upper 95% confidthe GIK group had a cTnI value of 13.1 ng/mL (GIK group,
38 The Journal of Thoracic and Cardiovascular Surgery ● Janua11/133 [8.3%]; placebo group, 26/137 [19.0%]; P  .021),
and 6-hour mean cTnI values were lower (GIK group, 6
ng/mL [95% confidence limits, 5.2-6.8]; placebo group, 9.0
ng/mL [95% confidence limits, 7.5-10.6]; P  .001).
ANOVA demonstrated a lower cTnI release over 12 hours
(P  .035) but no difference over 72 hours (P  .272,
Figure 4).
Metabolic Data
WBG concentration at baseline was similar but increased
in both groups during infusion, despite an escalating
protocol of supplemental insulin (Figure E1). More pa-
tients in the GIK group reached the criterion of a WBG
concentration of 180 mmol/L or greater for supplemental
insulin by the end of CPB (GIK group, 129/138 [93.5%];
placebo group, 29/142 [20.4%]; P  .001) and during the
12 hours after reperfusion (GIK group, 132/138 [95.7%];
placebo, 68/142 [47.9%]; P  .001). The total amount of
supplemental insulin used in recipients was 5-fold higher
in the GIK group (GIK group median, 49.6 IU [IQR,
37.1-72.5 IU]; placebo group median, 10 IU [IQR 7.1-
23.4 IU]; P  .001). Fifteen patients in the GIK group but
no patients in the placebo groups required intravenous
50% dextrose for a WBG value of less than 4 mmol/L.
Neurologic Outcomes
There was no difference in the incidence of type I or II
6 and 6 to 12 hours after reperfusion and cumulative
101) in all patients and in those receiving dopamine
limit. GIK, Glucose-insulin-potassium.0 to
/kg
enceneurologic deficits.
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POther Complications
There were no differences in the overall or specified inci-
dence of infection episodes requiring treatment. Also, the
incidence of reperfusion ventricular dysrhythmias and new
postoperative atrial dysrhythmias was no different between
groups. Extubation times and ICU and postoperative hospi-
tal lengths of stay were similar (Table 1).
Figure 4. Serum cardiac troponin I (cTnI) levels (ng/mL
Analysis was done with repeated-measures analysis
TABLE 1. Postoperative results
Variable GIK gro
Type I neurologic deficit, n (%) 2 (1.4)
Type II neurologic deficit, n (%) 11 (8)
Extubation time (min), median (IQR) 982 (708-
ITU stay (h), median (IQR) 28 (24-4
Hospital stay (d), median (IQR) 7 (6-10
Postreperfusion VF/VT, n (%) 20 (14.5)
Postoperative AF, n (%) 77 (55.8)
Treated infections, n (%) 42 (30.4)
Chest infection 24 (17.4)
UTI 4 (2.9)
SSWI 4 (2.9)
DSWI 4 (2.9)
LWI 11 (8.0)
Data on extubation and discharge time were transformed. GIK, Glucos
ventricular fibrillation; VT, ventricular tachycardia; AF, atrial fibrillation; UT
sternal wound infection; LWI, leg wound infection.
The Journal of ThoracMultivariable Analyses
By using binary logistic regression analysis, nonuse of GIK
was an independent predictor of myocardial injury, low
cardiac output episodes, and inotrope use (Table 2). Intra-
aortic balloon pump use (P  .001), postoperative infection
(P  .004), and use of vasoconstrictors (6-12 hours, P 
.003) increased the time to extubation. Increasing ITU
baseline to 72 hours after aortic crossclamp release).
riance. GIK, Glucose-insulin-potassium.
Placebo group P value
5 (3.5) .443
7 (4.9) .336
1030 (687-1308) .90
28 (24-49) .95
7 (6-11) .41
19 (13.4) .864
66 (46.5) .122
33 (23.2) .429
23 (16.2) .873
7 (4.9) .541
4 (2.8) 1
1 (0.7) .209
7 (4.9) .335
lin-potassium; IQR, interquartile range; ITU, intensive therapy unit; VF,
ary tract infection; SSWI, superficial sternal wound infection; DSWI, deep; from
of vaup
1361)
9)
)
e-insu
I, urinic and Cardiovascular Surgery ● Volume 131, Number 1 39
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use (P  .009), postoperative infection (P  .002), extu-
bation time (P  .001), and myocardial injury (P  .05).
NYHA class III or IV (P  .018), angina requiring intra-
venous nitrates (P  .026), postoperative infection (P 
.001), and ITU stay (P  .003) predicted overall postoper-
ative length of stay.
Discussion
This study demonstrates that perioperative systemic GIK in
on-pump CABG is associated with increased CI, lower
vascular resistance, fewer low cardiac output episodes, and
less cardiomyocyte injury. GIK treatment reduced the need
for inotropic support, even beyond the duration of infusion,
but increased vasoconstrictor use. In particular, the hemo-
dynamic benefits of GIK were apparent in patients with
heart failure symptoms and reduced ejection fraction,
whereas the myocardial protection effect was demonstrable
in the lower-risk patients. These findings are important
because previous studies have demonstrated that low car-
diac output, the need for inotropic support, and biochemical
evidence of myocyte injury are important risk factors for
prolonged ventilation, ITU stay, and early mortality after
CABG.1 Hyperglycemia after GIK administration was prev-
alent but was not associated with an increased incidence of
brain injury or infection episodes nor did it preclude re-
duced biochemical markers of myocardial injury, as has
been suggested by animal models of hyperglycemia during
myocardial ischemia.12 Postoperative cardiac surgical pa-
tients have significant insulin resistance after cooling, and
strict glycemic control might be difficult to achieve in the
TABLE 2. Multivariable predictors of myocardial injury, LC
Outcome Factor
Myocardial injury Nonuse GIK
NYHA class III/IV
Previous Q-wave MI
No preoperative ACE-I
LCOE 0-6 h after AXC off Nonuse GIK
Myocardial injury
Increasing age (per ye
NYHA III/IV
Inotrope use Nonuse GIK
Myocardial injury
Male sex
Increasing age (per ye
Increasing clamp time
NYHA III/IV
LMS disease
Binary logistic regression analysis was used. LCOE, low cardiac output ep
NYHA, New York Heart Association; MI, myocardial infarction; ACE-I, angio
coronary artery.perioperative period. Although active treatment of WBG
40 The Journal of Thoracic and Cardiovascular Surgery ● Januaconcentrations of greater than 120 mg/dL with intravenous
insulin benefits patients with sepsis and multiorgan failure
with longer ITU stays,8 the mechanism by which this is
achieved and its relevance to ischemic myocardial protec-
tion during cardiac surgery is unclear.
In experimental in vitro and in vivo models, GIK has
been shown to have both inotropic and vasodilator proper-
ties.13-15 Because we did not use load-independent methods
to assess myocardial contractility, the relative contribution
of these hemodynamic changes cannot be differentiated.
Our results, however, are consistent with a mechanism of
either improved protection or a vasodilator-inotropic re-
sponse to GIK and are concordant with previous smaller
studies of systemic GIK.16,17 Cardiomyocyte injury is a
recognized sequel of CABG, and the incidence we observed
is comparable with that seen in other studies.18 Previous
work has demonstrated a close relationship between ECG
evidence of ischemia-infarction and a cTnI level of 13.1
ng/mL, and this threshold was combined with ECG PMI as
our index of myocardial injury.10 Six-hour postoperative
cTnI levels of greater than 13.1 ng/mL were also predictive
of low cardiac output and have previously been associated
with increased early and 2-year cardiac mortality.18,19
In this study there was an intentional protocol restriction
of -blocker use until postoperative day 4. The observed
incidence of AF was high and, in contrast to previous
open-label studies and the results from the meta-analysis,9
was not reduced by GIK.16 GIK alone does not confer AF
protection, but our findings do not exclude a possible ad-
junctive antiarrhythmic effect.20 There was no effect on
and inotrope use
OR (95% CI) P value
2.86 (1.35-5.88) .006
2.9 (1.14-7.34) .025
2.29 (1.09-4.79) .028
2.22 (1.0-5.0) .05
2.22 (1.01-4.48) .027
3.3 (1.67-9.6) .004
1.06 (1.01-1.1) .014
3.26 (1.4-7.62) .002
3.57 (1.81-6.67) .001
3.3 (1.48-7.38) .013
2.52 (1.15-5.56) .022
1.05 (1.01-1.07) .022
minute) 1.04 (1-1.07) .033
3.26 (1.4-7.62) .006
2.19 (1.02-4.7) .045
s; OR, odds ratio; CI, confidence interval; GIK, glucose-insulin-potassium;
-converting enzyme inhibitor; AXC, aortic crossclamp; LMS, left main stemOE,
ar)
ar)
(per
isode
tensinreperfusion ventricular dysrhythmia.
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PCABG with CPB is associated with brain injury, which
could by exacerbated by perturbations in WBG concentra-
tion. Although GIK therapy produced episodes of hypogly-
cemia and hyperglycemia requiring treatment, careful mon-
itoring of WBG and discontinuation of supplemental insulin
1 hour before trial solution cessation minimized hypogly-
cemia, which, if detected, was promptly treated. We did not
observe any greater incidence of type I or type II neurologic
injury. However, any detrimental effect of hyperglycemia
might have been ameliorated by hypothermia during CPB or
by coadministration of insulin, which might be intrinsically
neuroprotective.21
The dose of GIK is comparable with that used in 2 large
acute myocardial infarction studies and in some surgical
studies that have demonstrated hemodynamic benefit in
postsurgical cardiogenic shock and in patients undergoing
urgent CABG.5-7,17,22 The optimal timing of GIK infusion
in relation to the myocardial ischemic period is undefined.
We started the infusion approximately 80 minutes before
aortic clamping and continued throughout ischemia and for
6 hours after reperfusion. The relative importance of pre-
ischemic, peri-ischemic, and postischemic administration is
unclear, but reperfusion of viable cardiomyocytes appears
crucial to its efficacy.23 Without reperfusion, hydrogen ion
and lactic acid accumulation frustrate the beneficial meta-
bolic and functional effects.24 Further studies are necessary
to discover its optimal timing, duration, and dosage and the
effects of subsequent glycemic control on outcome.
If GIK truly improves clinical myocardial protection, its
mechanisms of action might include metabolic protection
through promotion of cardiac glycolysis, upregulation of
glucose transport, and suppression of cardiac nonesterified
fatty acid metabolism.25,26 These might result in preserva-
tion of intracellular glycogen and high-energy phosphates
and a reduction of membrane lipid peroxidation.27,28 Fi-
nally, insulin might have anti-inflammatory, profibrono-
lytic,29 and antiapoptotic effects independent of known met-
abolic actions.30 The individual clinical effect of these
effects is unknown.
It is not known whether the findings are applicable to
warm on-pump or off-pump CABG techniques, in which
insulin resistance might be lower. It is possible that the
administration of norepinephrine augmented the hemody-
namic changes seen in the GIK group. However, norepi-
nephrine was commenced once a low SVR–high CI state
had been established at 15 minutes after protamine admin-
istration. Examination of CI over the time points before
norepinephrine use showed that GIK still increased CI (P 
.001). A subanalysis of norepinephrine recipients only demon-
strated a higher CI in the GIK group (P  .001, repeated-
measures ANOVA) and a lower SVRI (P  .008), despite
similar doses of norepinephrine, suggesting it was not contrib-
uting to the increased CI. Finally, a subanalysis of the CI data
The Journal of Thoracbetween groups in patients not requiring norepinephrine again
demonstrates a higher CI in the GIK group, although statistical
significance was not reached (GIK group, n  42; control
group, n  72; P  .111, log-transformed data, repeated-
measures ANOVA) and a significantly lower SVRI (P 
.035). The magnitude of the change in CI between nonnorepi-
nephrine and norepinephrine recipients was no different (P 
.807). Thus on the basis of these data, we conclude that GIK
truly increased CI but acknowledge the confounding effect
of norepinephrine use.
Postoperative hyperglycemia was prevalent, despite sup-
plemental insulin, and we did not change the insulin proto-
col once the study was in progress because this would have
been likely to generate more hypoglycemia in the placebo
group, thereby unblinding the study.
Systemic GIK has beneficial cardiovascular and myocar-
dial protective effects when administered in the periopera-
tive period in patients undergoing CABG without apparent
increased morbidity, even in the presence of hyperglycemia.
It can thus be considered an effective, inexpensive, and safe
adjunctive myocardial protective technique but necessitates
careful glucose monitoring. Further multicenter studies are
required to examine the effect of GIK on mortality, wider
aspects of morbidity, and resource use.
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etrist); Mark Wilkes, MB, FRCA (consultant anesthetist); Ian C.
Wilson, MD, FRCS (consultant cardiac surgeon).
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monary bypass (Intra CPB), and 0-12 hours after aortic crossclamp release. GIK, Glucose-insulin-potassium.The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 1 42.e1
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CSPTABLE E1. Preoperative and intraoperative variables
Variable GIK group Placebo group P value
Age (y), mean (SD)* 64.4 (8.8) 63.6 (9.07) .463
Sex* (male:female ratio) 6.3:1 4.3:1 .261
Body surface area (m2), mean (SD) 1.91 (0.19) 1.91 (0.18) .762
Treated hypertension, n (%) 71 (51.4) 64 (45.1) .339
Previous Q-wave MI, n (%)* 55 (39.9) 49 (34.5) .388
Angina requiring intravenous nitrates, n (%)* 6 (4.3) 8 (5.6) .785
Previous TIA/CVA, n (%) 3 (2.2) 6 (4.2) .501
Previous AF, n (%) 9 (6.5) 4 (2.8) .164
Preoperative medications, n (%)
Antiplatelets 128 (92.7) 137 (96.5) .192
-Adrenergic antagonists* 106 (76.8) 100 (70.4) .278
Angiotensin-converting enzyme inhibitor* 50 (36.2) 46 (32.4) .530
Potassium channel blocker* 40 (29) 29 (20.4) .127
Calcium channel antagonists* 72 (52.2) 77 (54.2) .811
Lipid-lowering agents* 108 (78.3) 122 (85.9) .118
Elective:urgent* 2.37:1 2.55:1 .79
Preoperative cholesterol (mmol/L), mean (SD) 4.26 (1.1) 4.4 (1) .123
CCS score, n (%) .240
I 10 (7.25) 7 (4.9)
II 41 (29.7) 60 (42.3)
III 50 (36.2) 41 (28.9)
IV 37 (26.8) 34 (23.9)
NYHA class, n (%)* .423
I/II 117 (84.8) 133 (86.7)
III/IV 21 (15.2) 19 (13.3)
Parsonnet score, median (IQR) 4 (2-8.25) 4 (1.75-10) .89
LV function, n (%)* .89
EF 50% 99 (71.7) 100 (70.4)
EF 50% 39 (28.3) 42 (29.6)
LMS stenosis 50%, n (%)* 33 (23.9) 22 (15.5) .098
Preischemic infusion time (min), mean (SD)* 82 (23.8) 84 (24.4) .527
CPB time (min), mean (SD)* 88.3 (25.2) 88.8 (28.4) .858
AXC time (min), mean (SD)* 48.9 (15.6) 47.5 (18.5) .508
GIK, Glucose-insulin-potassium; SD, standard deviation; MI, myocardial infarction; TIA, transient ischemic attack; CVA, cerebrovascular accident; AF, atrial
fibrillation; Urgent, coronary artery bypass grafting performed during admission episode for unstable angina–acute coronary syndrome; CCS, Canadian
Cardiovascular Society; NYHA, New York Heart Association; IQR, interquartile range; LV, left ventricular; EF, ejection fraction (estimated by means of
ventriculography or echocardiographically); LMS, left main stem; Preischemic infusion time, time from infusion start to aortic crossclamp; CPB,
cardiopulmonary bypass; AXC, aortic crossclamp. *Factor that was included in the multivariable analyses. Significant myocardial injury was included as
an additional factor for low cardiac output episodes and dopamine requirements 0 to 6 hours after release of aortic crossclamp.
42.e2 The Journal of Thoracic and Cardiovascular Surgery ● January 2006
